{
    "eid": "2-s2.0-85104272028",
    "title": "Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review",
    "cover-date": "2021-09-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hepatology",
            "@code": "2721",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Gastroenterology",
            "@code": "2715",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Chronic hepatitis B",
        "Hepatitis B core-related antigen",
        "Hepatitis B virus RNA",
        "Nucleos(t)ide analogues",
        "Relapse"
    ],
    "authors": [
        "Aunchalee Jaroenlapnopparat",
        "Maneerat Chayanupatkul",
        "Pisit Tangkijvanich"
    ],
    "citedby-count": 4,
    "ref-count": 42,
    "ref-list": [
        "Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013",
        "Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis",
        "Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries",
        "Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss",
        "Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely",
        "2017 clinical practice guidelines on the management of hepatitis B virus infection",
        "Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update",
        "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance",
        "Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors",
        "Discontinuation of oral antivirals in chronic hepatitis B: a systematic review",
        "The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian patients with chronic hepatitis B: a systematic review",
        "Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA",
        "Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection",
        "Serum hepatitis B virus RNA as a potential diagnostic biomarker during chronic hepatitis B virus infection",
        "The role of cccDNA in HBV maintenance",
        "Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients",
        "Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy",
        "JSH Guidelines for the Management of Hepatitis B Virus Infection",
        "Prediction of sustained response after nucleo(s)tide analogue cessation using Hbsag and Hbcrag levels\u2014a multicenter study (CREATE)",
        "Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation",
        "Hepatitis B surface antigen, core-related antigen, and HBV RNA: predicting clinical relapse after NA therapy discontinuation",
        "Serum HBV RNA dynamic and drug withdrawal predictor value in patients with chronic HBV infection on long-term nucleos(t)ide analogue (NA) therapy",
        "Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy",
        "Combining HBV RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B patients",
        "Incidence and factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU/mL",
        "Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B",
        "Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy",
        "Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B",
        "Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk",
        "Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound",
        "Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients",
        "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update",
        "Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients",
        "Serum hepatitis B virus DNA, RNA, and HBsAg: which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment?",
        "Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection",
        "Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B",
        "Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg \u2264 200 IU/mL",
        "Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-na\u00efve HBV-infected individuals",
        "Correlation of HBcrAg with intrahepatic hepatitis B virus total DNA and covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients",
        "Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed",
        "Hepatitis B virus serum DNA andRNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Complementary Medicine for Gastrointestinal and Liver Diseases Research Unit",
        "Chulalongkorn University",
        "Thailand Research Fund",
        "Faculty of Medicine, Chulalongkorn University"
    ]
}